MATRIX METALLOPROTEINASE -2 GENE VARIABILITY IN PSORIASIS
| Authors | |
|---|---|
| Year of publication | 2009 |
| Type | Article in Proceedings |
| Conference | 6th EADV Spring Symposium on Psoriasis |
| MU Faculty or unit | |
| Citation | |
| Field | Dermatovenerology |
| Keywords | psoriasis; matrix metalloproteinase 2; polymorphism; comorbidity |
| Description | The expression of matrix metalloproteinase-2 was observed to be significantly up regulated in psoriasis. The aim of the study is to associate a DNA polymorphic genotype in MMP-2 promoter gene with psoriasis and/or with psoriasis phenotypes. A total of 386 Czech psoriatic patients were compared to 196 controls of similar age and sex distribution, without personal or family history of chronic skin diseases. In all 580 Czech persons, four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) were detected by PCR methods. A significant association of GG genotype of -790 MMP-2 polymorphism with psoriasis was observed (Pcorr=0.04). Although no differences in the associated GG(-1575)CC(-1306)TT(-790) MMP-2 promoter genotype frequency between psoriasis patients and controls had been found, the genotype was observed to be highly significantly lower in patients with family history of psoriasis (close as well as distant), family history of diabetes and personal history of allergy (odds ration for GGCCTT in the group is 0.11, 95% confidential interval 0.02-0.50, Pcorr= 0.01). The GGCCTT MMP-2 promoter genotype was observed to be less frequent in patients with all three positive characteristics compared to psoriatic patients without them (odds ratio=0.15, 95% CI = 0.03-0.72 for psoriatic patients with family history of psoriasis and diabetes and with allergy P=0.007, Pcorr= 0.04;). MMP-2 located at psoriasis susceptibility region on 16q (psoriasis susceptibility 8, PSORS8) can be considered a gene-modulator of psoriasis. In the future, similar genetic characteristics could contribute to data assembly of genetic predisposition to psoriasis and could lead to therapy improvement based on time-proved individual pharmacogenetic aspects detected in psoriasis patients. |
| Related projects: |